FGP
KURA icon

Freestone Grove Partners’s Kura Oncology KURA Stock Holding History

Freestone Grove Partners’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,682
Closed -$130K – 774
2025
Q1 		$130K Buy
+19,682
New +$153K ﹤0.01% 555

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Grove Partners's KURA Position: Q2 2025 in Review

Freestone Grove Partners sold out of Kura Oncology (KURA) in Q2 2025, closing a stake of 19,682 shares — an estimated $130K sold.

Freestone Grove Partners first reported a position in KURA in Q1 2025 and held it in 1 quarter. The position peaked at $130K in Q1 2025. 182 funds tracked by Wall St. Rank hold KURA as of Q2 2025.

  • Freestone Grove Partners reported no remaining Kura Oncology position as of Q2 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 19,682 Kura Oncology shares in Q2 2025, an estimated $130K.
  • Freestone Grove Partners first reported a position in Kura Oncology in Q1 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Kura Oncology position peaked at $130K in Q1 2025.
  • 182 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2025.

Based on Freestone Grove Partners's 13F filing for Q2 2025, filed 14 Aug 2025.